Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMP-001 and Pembrolizumab in Relapsed and Refractory Lymphomas
NCT03983668Phase 2Terminated
- Start
- Jan 2020
- Primary completion
- Aug 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vidutolimod in lymphoma. Primary endpoints: Dose Limiting Toxicities up to 2 years and Objective Response Rate up to 2 years. Started Jan 2020; status: terminated.
02
Drugs
vidutolimod
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT03983668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983668.